

Feeding and Autoimmunity in Down's syndrome Evaluation Study (FADES)

Submission date 23/07/2014	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 08/04/2015	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 17/01/2023	Condition category Genetic Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Children with Down's Syndrome (DS) have an increased risk of autoimmune conditions where the body's immune system attacks its own cells, such as thyroid problems, diabetes and coeliac disease. There is some evidence that prolonged breastfeeding protects against diabetes and coeliac disease. We think that in infants with DS early feeding practices may be related to the development of autoimmunity. Children with DS may have difficulties with breastfeeding, leading to rapid introduction of formula feeds. We aim to study the association between early infant feeding, infections and the development of autoimmunity.

Who can participate?

Babies less than 8 months old with DS.

What does the study involve?

Parents will be asked to complete questionnaires at the start of the study detailing family history, birth history, weight, medical problems and early feeding. They will have further feeding questionnaires at 7 and 12 months, and medical questionnaires annually until the age of 5 years. Samples will be collected at the start of the study including faeces, a brushing from the infant's cheek for genotyping (looking at their DNA), a blood sample to look at autoantibody production (antibodies which act against their own cells), and a urine specimen to detect development of diabetes. Further stool, urine and blood samples are collected at 6 months, 12 months and yearly thereafter until 5 years of age.

What are the possible benefits and risks of participating?

There are not any risks to taking part in the study. The heel/finger prick tests may cause some minor discomfort but there will only be seven of these over a five-year period. The participants will have additional questionnaires and samples to collect which families with a child with DS do not normally have to do. Apart from the initial blood test these samples can all be done at home if the parents feel able to do this or can be taken at the child's routine appointments and will not require any additional hospital attendances. We wish to try and find out what difficulties babies with DS have with feeding and infections and how this may contribute to the development of autoimmunity. Whilst our findings may not directly help the participants they may benefit children born with DS in the future and we are therefore relying on the research participants

goodwill. From this study we hope to go on and do a further study to develop an intervention to help with feeding in babies born with DS. We also hope the study will increase knowledge in this area for the parents of children with DS as well as those that care for them.

Where is the study run from?
University of Bristol (UK)

When is the study starting and how long is it expected to run for?
July 2014 to January 2022

Who is funding the study?
NIHR Biomedical Research Unit in nutrition, diet and lifestyle at University Hospitals Bristol NHS Foundation Trust and University of Bristol (UK)

Who is the main contact?
Dr Georgina Williams

Contact information

Type(s)
Scientific

Contact name
Dr Georgina Williams

Contact details
NIHR Bristol Nutrition BRU
Level 3, University Hospitals Bristol Education Centre
Upper Maudlin Street
Bristol
United Kingdom
BS2 8AE

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
16735

Study information

Scientific Title
Feeding and Autoimmunity in Down's syndrome Evaluation Study (FADES): an observational cohort study

Acronym

FADES

Study objectives

This study will aim to establish the feasibility of developing a cohort from across the UK of children with Down's Syndrome in whom we can study how feeding and early infections may be related to the increased risk children with Down's Syndrome have of developing thyroid, coeliac disease and diabetes.

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee South West – Central Bristol, 23/04/2014, ref: 14/fw0030

Study design

Non-randomised; Observational; Design type: Cohort study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Prevention

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Topic: Children; Subtopic: All Diagnoses; Disease: Down's syndrome, autoimmunity

Interventions

Phase 1: Samples will be collected by parents on the ward from their baby's nappy. The samples need to be 'fresh' (passed within an hour) and they will need to take three samples from the same 'dirty nappy' (i.e. from the same stool). In order to acquire a 'fresh' stool we will ask parents to check their baby's nappy regularly within one hour after a feed as babies tend to have a pronounced gastro-colic reflex. – I don't think this needs to be included as not part of the main study

Phase 2: Parents will be asked to complete questionnaires at baseline detailing family history, birth history, weight, medical problems and early feeding. They will have further feeding questionnaires to complete at 7 months and 12 months, and medical questionnaires annually until the age of 5 years. Samples would be collected at baseline including faeces to look at gut microbiome, a brushing from the infant's cheek for genotyping, a blood sample to look at development of auto-antibody production (specifically autoantibodies to insulin, GAD, IA-2 and

ZnT8R/W, which are all associated with type 1 diabetes, anti-BSA antibody, antibodies to tissue transglutaminase (Tg), antibodies to thyroid peroxidase (TPO), antibodies to gastric H⁺/K⁺ ATPase 4A), and a urine specimen for urinary c peptide to detect development of diabetes. Further stool, urine and blood samples will be collected at 6 and 12 months and once a year thereafter until 5 years of age.

Intervention Type

Other

Primary outcome measure

As a feasibility study the primary outcome is to have established a cohort of children with Down's syndrome in which we have been able to record early feeding practice and obtain samples from which we can study the development and natural history of autoimmunity in relation to feeding and the gut microbiome.

Secondary outcome measures

Comparing babies with Down's syndrome who have breastfed with those that have not, we will be studying:

1. Whether they have significant differences in autoantibody status
2. Whether they have differences in the diversity of their gut microbiomes

We would also be investigating the correlation between levels of anti-BSA antibodies and correlate with autoantibody positivity in all participants who had been exposed to cow's milk protein.

Overall study start date

01/07/2014

Completion date

01/01/2022

Eligibility

Key inclusion criteria

Babies recruited antenatally or in the first 8 months of life born with Down's syndrome (three copies of chromosome 21) as confirmed by karyotype after birth

Participant type(s)

Patient

Age group

Neonate

Sex

Both

Target number of participants

Planned Sample Size: 200; UK Sample Size: 200

Key exclusion criteria

1. Babies with Down's syndrome who have a child protection plan or who are no longer with their birth mother
2. Babies with Down's syndrome over 8 months of age
3. Babies with Down's syndrome in whom the parents do not speak English

Date of first enrolment

01/07/2014

Date of final enrolment

01/07/2016

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

The National Institute for Health Research Biomedical Research Unit in Nutrition, Diet and Lifestyle

University Hospitals Bristol NHS Foundation Trust

University of Bristol

Bristol

United Kingdom

BS2 8AE

Study participating centre

Over 200 sites

United Kingdom

-

Sponsor information

Organisation

University of Bristol

Sponsor details

Research Enterprise and Development

Senate House

Tyndall Avenue

Clifton

England
United Kingdom
BS8 1TH

Sponsor type
University/education

ROR
<https://ror.org/0524sp257>

Funder(s)

Funder type
Government

Funder Name
NIHR Biomedical Research Unit (BRU) (UK)

Results and Publications

Publication and dissemination plan
To be confirmed at a later date

Intention to publish date

Individual participant data (IPD) sharing plan
Not provided at time of registration

IPD sharing plan summary
Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/11/2022	17/01/2023	Yes	No